Collegium Pharma (COLL): Notes From Senior Management Meeting - Piper Jaffray

October 12, 2016 10:05 AM EDT
Get Alerts COLL Hot Sheet
Price: $14.91 -0.27%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 16 | New: 11
Trade COLL Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Collegium Pharmaceutical (NASDAQ: COLL) after having the opportunity to speak with Collegium senior management and coming away with additional details on the payer landscape for Xtampza ER.

This information reinforced the view that prescription (Rx) volumes for the product will ramp aggressively into 2017 and beyond. Specifically, COLL remains in advanced discussions with additional large payers, suggesting that further developments on the contracting front are likely in the near-term. The analyst is modeling peak Xtampza ER sales in the neighborhood of $500M if patents listed in the FDA Orange Book expire around March 2025.

No change to the price target of $23.

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $17.66 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray

Add Your Comment